These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24988935)

  • 21. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
    Latham BD; Geffert RM; Jackson KD
    Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase: comparative studies using in vitro, in situ and in vivo models.
    Sun H; Bi H; Huang M; Liu D; Qin Z
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):486-94. PubMed ID: 20936649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
    Peters S; Zimmermann S; Adjei AA
    Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.
    Wulkersdorfer B; Zeitlinger M; Schmid M
    Clin Pharmacokinet; 2016 Jan; 55(1):47-77. PubMed ID: 26201307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicity.
    Paludetto MN; Puisset F; Chatelut E; Arellano C
    Med Res Rev; 2019 Nov; 39(6):2105-2152. PubMed ID: 31111528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiological differences in haematological malignancies between Europe and China.
    Chen XC; Chen XZ
    Lancet Oncol; 2014 Oct; 15(11):e471-2. PubMed ID: 25281463
    [No Abstract]   [Full Text] [Related]  

  • 29. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
    Nelson MH; Dolder CR
    Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically relevant drug interactions between anticancer drugs and psychotropic agents.
    Yap KY; Tay WL; Chui WK; Chan A
    Eur J Cancer Care (Engl); 2011 Jan; 20(1):6-32. PubMed ID: 20030690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
    Zaibet S; Vauchier C; Khoudour N; Roulleaux Dugage M; Korb-Savoldelli V; Alexandre J; Blanchet B; Goldwasser F; Thomas-Schoemann A; Bellesoeur A
    Bull Cancer; 2018 Nov; 105(11):1102-1109. PubMed ID: 30309623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].
    Bartal A; Mátrai Z; Szucs A; Belinszkaja G; Langmár Z; Rosta A
    Orv Hetil; 2012 Jan; 153(2):66-78. PubMed ID: 22217686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism considerations for kinase inhibitors in cancer treatment.
    Duckett DR; Cameron MD
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1175-93. PubMed ID: 20684746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
    Guan YS; He Q
    Expert Opin Pharmacother; 2011 Feb; 12(2):303-13. PubMed ID: 21226640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.
    Ferrer F; Tetu P; Dousset L; Lebbe C; Ciccolini J; Combarel D; Meyer N; Paci A; Bouchet S
    Crit Rev Oncol Hematol; 2024 Aug; 200():104385. PubMed ID: 38810843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits].
    Bouchet S; Royer B; Le Guellec C; Titier K;
    Therapie; 2010; 65(3):213-8. PubMed ID: 20699073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
    Siegel-Lakhai WS; Beijnen JH; Schellens JH
    Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.